SREBF1 and metabolic dysfunction-associated steatotic liver disease: TMAO contributes to the progression of MASLD primarily by promoting the expression of SREBP-1c, a critical regulator of liver lipid metabolism that increases triglyceride synthesis and favors the progression of hepatic steatosis [24].